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Abstract In the drive to replace chlorofluorinated hydrocarbons (CFCs) by alternative more environmentally friendly 
propellants in pressurized metered dose inhalers (pMDls), Chiesi has developed new inhalers using Modulite@ technology. 
The aim was to obtain CFC-free pMDls which are equivalent, in terms of safety and efficacy, to the previous CFC devices 
at the same dose. When beclometasone dipropionate (BDP) and budesonide Modulite@ formulations were compared to 
the equivalent CFC products there was no significant difference in morning serum cortisol or urinary cortisol excretion, 
at the maximum recommended daily dose (2000 pg or I600 pg respectively). 
Single dose pharmacokinetic studies in both healthy volunteers and asthmatic patients compared systemic exposure 
(BI7MP levels) for BDP-CFC with BDP Modulite@ and extrafine BDP-HFA (QVAR@). Bl7MP levels for BDP-CFC and 
BDP Modulite@ were comparable, but substantially less than that seen with extrafine BDP-HFA 
After 6 weeks of treatment in asthmatic patients, B I7MP AUC after inhalation of BDP (I 000 pg twice-dally) from BDP 
Modulite@ was comparable with that obtained after BDP-CFC (Becloforte@). Plasma profile of BDP and B I7MP were 
similar after inhalation from BDP Modulite@ with standard actuator or delivered via a spacer; suggesting that pulmonary 
delivery of BDP to the lung is similar with both actuators. 
02002 Elsevier Science Ltd 
INTRODUCTION 
Inhalation is regarded as the preferred route for the 
treatment of airways disease because it delivers drugs to 
the site where they are needed. As a result, reduced 
doses can be administered, compared with systemic 
therapy, decreasing the potential for systemic exposure 
and improving the adverse-event profile.As a means of 
administering inhaled drugs, the pressurized metered 
dose inhaler (pMDI), rather than the dry powder inhaler, 
is currently the device of choice for asthma inhalation 
therapy. The pMDl is well-established as a safe and 
reliable delivery system and it is the device most widely 
used by adults with asthma (I), estimated to comprise 
around 68% of the total world-wide inhaled drug market. 
There are two major classes of inhaled therapy 
established for the treatment of reversible obstructive 
airways disease: bronchodilators and anti-inflammatory 
agents, generally steroids. Beclometasone dipropionate 
(BDP) and budesonide (BUD) are widely used topically 
active synthetic glucocorticosteroids. pMDls containing 
BDP or BUD with chlorofluorinated hydrocarbon (CFC) 
propellants (e.g. trichloro and dichlorofluoromethane) 
have been in use for more than 20 years. In the drive to 
replace CFCs by alternative more environmentally 
friendly propellants in pMDls, Chiesi Farmaceutici has 
developed new pMDl products using the Modulite@ 
technology. In Modulite@ pMDls, the drug is dissolved in 
the propellant, HFA I34a (Norflurane), with the aid of a 
co-solvent such as ethanol.The vapour pressure of the 
propellant, the proportion of co-solvent and the 
dimensions of the actuator orifice will largely determine 
the spray pattern from such a formulation. The final 
particle size distribution then depends on the drug 
concentration in a droplet and any other non-volatile 
components, which have been added.The permutation of 
these factors allows the design of a drug product with a 
chosen particle size distribution (2). The aim was to 
obtain hydrofluoroalkane (HFA) products therapeutically 
equivalent at equal doses in terms of safety and efficacy 
to the previous CFC devices. 
BACKGROUND INFORMATION ON 
THE PHARMACOKINETICS AND 
PHARMACODYNAMICS OF INHALED 
BDP AND BUD 
It is known that BDP is a pro-drug with weak 
glucocorticoid receptor binding affinity that is hydrolysed 
via esterase enzymes to the active metabolite 
beclometasone- I7-monopropionate (BI 7MP) (3). The 
absolute bioavailability following inhalation of the CFC 
product is approximately 2% and 62% of the nominal 
dose for unchanged BDP and B I7MP respectively (4). 
Systemic absorption of unchanged BDP occurs mainly 
through the lungs with negligible oral absorption of the 
swallowed dose. The systemic absorption of B I7MP 
arises from both lung deposition and oral absorption of 
the swallowed dose. The bioavailability of orally 
administered BDP is negligible but pre-systemic 
conversion to BI 7MP results in absorption of 
approximately 40% of the swallowed portion as B I7MP 
There is an approximately linear increase in systemic 
exposure with increasing inhaled dose (S).The terminal 
elimination half-lives are 0.5 hours and 2.7 hours for 
BDP and B I7MP respectively (4). 
Plasma protein binding is moderately high; BDP is 
cleared very rapidly from the systemic circulation, by 
metabolism mediated via esterase enzymes that are 
found in most tissues (6). The main product of 
metabolism is the active metabolite (BI7MP). Minor 
inactive metabolites, beclometasone-2 I -monopropion- 
ate (B2 I MP) and beclometasone (BOH), are also formed 
but these contribute little to the systemic exposure. 
B I7MP metabolite is the most active with approximately 
30 times the potency of BDP BI 7MP is also the most 
abundant metabolite in the plasma. Therefore the 
majority of the systemic corticosteroid effects will be 
related to B I7MP systemic exposure (7). 
BUD is a racemic mixture of R and S epimers. In vitro, 
no inter-conversion between the two epimers has been 
observed. BUD has a high relative affinity for the 
glucocorticoid receptor and the R epimer has 2-fold 
greater affinity than the S epimer (8). BUD is a mod- 
erately lipophilic compound that shows a rapid uptake 
into the airway mucosa. Although topical BUD is 
rapidly and extensively absorbed through the lung, 
there is no evidence of intrapulmonary drug 
metabolism apart from conjugation with fatty acids. In 
vitro tests did not demonstrate any oxidative or 
reductive metabolism of BUD by human lung 
homogenate. Budesonide is metabolized by cytochrome 
P450 3A in human liver (9). Elimination half-life was 
about 2.7 hours for both epimers after intravenous 
administration and a similar elimination half-life was 
observed after inhalation route.The oral bioavailability 
of BUD was about IO%, with approximately 90% of the 
dose subject to first pass metabolism in the liver (8). 
There is an approximately linear increase in systemic 
exposure with increasing inhaled dose from 400 to 
I600 ug (IO). BUD systemic absorption arises from 
both lung deposition, that may vary from IO to 30% 
depending on the device and user technique, and oral 
absorption of the swallowed dose. 
The systemic pharmacodynamic effects of BDP and 
its metabolites and BUD can be assessed by measuring 
the hypothalamus-pituitary adrenal (HPA) function that 
is a biomarker of the systemic activity of any exogenous 
corticosteroid, including those taken by inhalation. It 
has been well documented that doses up to 400 ug 
BDP in adults have no measurable effect on 
endogenous cortisol levels. The maximum recom- 
mended dose of BDP (2000 ug) does show reductions 
in endogenous cortisol of approximately 40% in healthy 
volunteers (5). Doses up to 400 ug day-’ of BUD via 
Turbuhaler@ have no measurable effect on endogenous 
cortisol levels in adult asthmatic patients (I I) while a 
minimal systemic effect on plasma cortisol (12) has 
been observed at 800 ug day -I; at I600 ug day -I, the 
maximum BUD adult dose, a transient reduction in 
endogenous cortisol of approximately 20% in asthmatic 
patients (I I) and of 41% in healthy volunteers (I 2) was 
observed. 
SYSTEMIC PHARMACODYNAMIC 
EFFECTS OF MODULITE@ 
FORMULATIONS 
The effect of BDP Modulite@ on the HPA axis has been 
compared with BDP-CFC (Becloforte@, GSK) 2000 ug 
(8 x 250 ug) in a crossover study conducted in I2 
healthy volunteers (I 3). 
There was a similar reduction in serum cortisol (about 
40% decrease) and in urinary cortisol excretion (45% 
decrease), for both treatments (Figure I). 
In a separate study, extrafine BDP-HFA (Beclazone&, 
Baker Norton) showed significantly greater 24h cortisol 
suppression than BDP-CFC (Becloforte@, GSK) after a 
single 2000 ug dose (5). 
The relative effect of BUD Modulite@ on HPA axis has 
been compared with that of currently available BUD 
inhalers products, Pulmicort@ CFC pMDl (BUD-CFC) 
and PulmicortTurbohaler@ (BUD-DPI) (Astra-Zeneca), in 
a three-way crossover, single dose study in I2 mild 
asthmatic patients (I 4). 
No difference in the serum cortisol concentration 
versus time curves (Figure 2) or in the urinary cortisol 
excretion between the three different BUD formulations 
has been observed. 
DOES PHARMACEUTICAL DATA 
PREDICTTHE SAFETY PROFILE? 
DATA FROM VOLUNTEERS 
In vitro characterization of aerosol formulations normally 
with Andersen Cascade lmpactor (ACI) is important in 
guiding pharmaceutical product development and is used 
in final quality control.The efficiency of delivery to the 
lung is dependent on particle size. It is generally agreed 
that particles below 4.7 urn reach the lungs while larger 
particles will deposit in the mouth and are swallowed 
( I5,I6). 
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FIGURE I. Mean serum cortisol profile and urinary excretion (normalized for urinary creatinlne) in healthy volunteers (n= 12) after 
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FIGURE 2. Mean serum cortisol profile in mild asthmatic 
patients (R = I 2) after inhalation of a single I 600 pg dose of BUD 
Modulitem’. BUD-CFC and BUD-DPI. 
BDP 
Twelve healthy volunteers were enrolled into a single 
IO00 ug dose, three-way crossover, pharmacokinetic 
study of three different BDP pMDl formulations: BDP 
Modulite@ with spacer (Jet@) (Beclojet@ 250) MMAD 
(mean mass aerodinamic diameter) 26 urn, extrafine 
BDP-HFA (QVAR@ 100, 3M Pharmaceuticals) MMAD 
I.2 pm, Chiesi BDP-CFC with spacer (Jet@) (Clenil 
Forte@ 250) MMAD 4.7 urn (I 7) (Figure 3). 
The area under the concentration-time curve (AUC) 
for BDP and its metabolite BI 7MP were assessed 
following inhalation from each pMDl product.The AUC 
calculated for BI 7MP during the first hour after 
inhalation AUC(,,,) and BDP AUC,,,, (calculated up to 
the last measurable plasma concentration) were likely to 
reflect lung rather than gut absorption, since BDP is 
rapidly metabolized to B I7MP in the lung.The AUCs for 
BDP and BI 7MP were significantly greater with the 
extrafine BDP-HFA formulation than with the BDP-CFC 
and BDP Modulite@ Jet@ formulations (Figure 4). 
BDP from the extrafine BDP-HFA pMDl was more 
raoidly absorbed into the systemic circulation as r 
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FIGURE 3. Distribution of BDP in the Andersen Cascade 
lmpactor stages. 
shown by BI7MPAUC~a_,,).The change in MMAD from 
4.7 urn to 2.6 urn had a negligible influence on BDP 
absorption, with AUCs for BDP and BI 7MP only 
slightly increased, while the change in MMAD from 
2.6 pm to I.2 urn was associated with a marked 
increase in absorption. 
A relationship was seen between the amount 
deposited in the ACI stages 3 to 6 (aerodynamic 
diameter between 4.7 and 0.7 urn) and AUCs (Figure 5). 
The in vitro and pharmacokinetic data suggest that 
from the safety viewpoint the transition from BDP-CFC 
to BDP Modulite@ can occur without any dose 
adjustment. 
BUD 
The systemic exposure to BUD epimers, following a 
single inhalation of I600 ug (8 x 200 pg shot-‘), from 
two BUD Modulite@ pMDls with different orifice 
diameter (0.30 and 0.42 mm) was assessed in six healthy 
volunteers (I 8). The fine particle dose (FPD < 4.7 pm) 
for both epimers is higher with the 0.30 mm compared 
with the 0.42 mm orifice (29. I vs. 16.8 UP for eoimer R. 
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FIGURE 5. RelationshIp between median AUCs of BDP and B I7MP vs MMAD and BDP recotier-ed In stage 3 lo 6 AC1 
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FIGURE 6. Distribution of R and S budesonide eplmers It- the Andersen Cascade lmpactor stages after ten cumulative shots oi BlJilj 
Modulite@ formulation. 
and 19.7 vs. I I .4 pg for epimer S respectively) and the 
MMAD was slightly lower with the smaller orifice 
(3. I pm, vs. 3.5 pm) (Figure 6). 
BUD plasma levels peak immediately after 
administration and reflect mainly lung absorption. 
Overall BUD bioavailability was 30% (S epimer) and 40% 
(R epimer) higher using the actuator with the smaller 
orifice, suggesting that an increase in the FPD increases 
the peripheral lung deposition with consequent higher 
systemic absorption. However, absorption rate and 
elimination half-life were unaffected by the change in the 
orifice diameter with the exception of a slightly reduced 
elimination half-life of S epimer (Figure 7). 
The choice of a different actuator orifice allows 
modulation of the fine particle dose to provide 
Modulite@ HFA pMDls matching different marketed BUD 
inhalers. 
SYSTEMIC EXPOSURE IN PATIENTS 
The pharmacokinetics of BDP after inhalation from 
BDP Modulites have been compared with a reference 
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FIGURE 7. BUD epimers median plasma levels in six healthy volunteers after inhalation of a I6OOFg dose of BUD Modulite” pMDls 
with different orifice diameter (0.30 and 0.42 mm). 
BDP-CFC product (Becloforte@, GSK) in adult patients 
with moderate-to-severe persistent asthma (I 9). 
Thirty-two adult patients with moderate/severe 
asthma entered a double-blind, double-dummy, 
randomized, parallel-group study.They were randomly 
assigned to 2000 pg BDP daily (1000 pg twice-daily) 
from either BDP Modulite@ or BDP-CFC both inhaled 
via a spacer device (Volumatic@, GSK). Pharmacokinetic 
sampling was carried out after 6 weeks of treatment 
following the last morning administration.Twenty-eight 
patients (I3 male and I5 female) completed the 
pharmacokinetic study. Unchanged BDP plasma levels 
were very low, and below the detection limit shortly 
after inhalation; therefore the pharmacokinetic 
evaluation was performed for the active BI 7MP 
metabolite only.The total systemic exposure to B I7MP 
represented by the plasma AUC over the dosing 
interval (AUC,) at steady-state in asthmatic patients, 
after inhalation of BDP (I 000 pg twice-daily) from BDP 
Modulite@ (AUC,: 2 I24 pg ml -1 h) was comparable 
with that obtained after BDP-CFC (AUC,: 
2 I60 pg ml -I h). The small difference observed in the 
initial absorption rate for BI 7MP with a higher C,,, 
and an earlier T,, with BDP Modulite@ appears to be 
due to a rapid initial absorption rate from the lung, 
rather than a difference in pulmonary deposition, since 
the plasma AUC values are comparable (AUC, ratio: 
0.98) (Figure 8). 
The difference in C,,, observed for the Modulite@ 
product is unlikely to result in differential pharmaco- 
logical effects, since the systemic effects of cortico- 
steroids (such as HPA axis suppression) are correlated 
with the total systemic exposure rather than peak 
concentrations (20). In contrast to these findings, the 
AUC and C,,, for BI 7MP obtained with both 
extrafine HFA formulations of BDP (QVAR@ and 
Beclazone@) have been reported to be between two 
and three times higher than the CFC reference 
product (5,2 I). 
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FIGURE 8. B I7MP mean (SD) plasma concentration-time 
profiles for asthmatic patients at steady-state after IO00 pg BDP 
twice-daily from either BDP Modulite@ or BDP-CFC. 
INFLUENCE OF CHARCOAL BLOCK 
AND OF A SPACER DEVICE ON 
PULMONARY DEPOSITION AND 
SYSTEMIC EXPOSURE 
The effects of a charcoal block and the use of the spacer 
(let@) on the absorption of BDP and BI 7MP after BDP 
Modulite@ have been studied in six healthy subjects after 
inhalation of a single dose of BDP (1600 pg), using a 
crossover design (22). BDP and B I7MP plasma levels were 
determined over a I2 hours period.The charcoal block did 
not affect the plasma levels of BDP, confirming that BDP 
found in the systemic circulation arises almost entirely 
from BDP absorbed unchanged from the lung, and that 
swallowed BDP is not bioavailable due to the pre-systemic 
conversion to BI 7MP As regards BI 7MP plasma levels, 
these were only slightly reduced (less than 20%) by the 
charcoal block, confirming that the pulmonary absorption 
is the main source of systemic exposure to BI 7MP The 
BDP and B I 7MP plasma profiles after inhalation from BDP 
Modulite@ with standard actuator or from the same 
formulation delivered via the spacer were virtually 
BDP 
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FIGURE 9. Plasma BDP and B I7MP following Inhalation of BDP Modulate W / 600 kg with or- wIthout ~harcodl bloci~ and with space:- 
(JetTM) (median ~6). 
identical, suggesting that pulmonary delivery of BDP to the 
lung is similar with and without spacer (Figure 9). 
CONCLUSIONS 
The Modulite@ formulations of inhaled steroids in HFA 
are equivalent, in term of safety, to the marketed (CFC 
and DPI) inhalers. The extent of cortisol suppression 
evaluated in healthy volunteers and patients using the 
maximum recommended dose (2000 pg BDP and 
1600 bg BUD) was comparable for both cortico- 
steroids. The similarity of the systemic pharmaco- 
dynamic effects produced by the products is consistent 
with the in-vitro data. 
By combining Modulite@ formulations with different 
orifice diameters, it has been possible to manipulate the 
fine particle dose so that they closely match currently 
available inhalers. 
Systemic exposure for Modulite@ formulations are 
comparable with CFC products at the same dose. 
Pharmacokinetic studies performed, in both healthy 
volunteers and in asthmatic patients, using the standard 
actuator and an actuator incorporating a spacer 
demonstrated that the systemic exposure was 
comparable for Modulite@ inhaler and CFC inhaler. 
Systemic exposure of BDP Modulite@ is substantially 
less than for the extrafine BDP-HFA pMDl (QVAR@ 3M) 
for which an adjustment of the dose is required. 
After BDP Modulite@ inhalation, the systemic 
exposure of BDP is unaffected by the spacer device and 
only slightly reduced by the charcoal block, confirming 
the optimal lung deposition of the corticosteroid. 
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